Associations of Bowel Movement Frequency with Risk of Cardiovascular Disease and Mortality among US Women

Wenjie Ma, Yanping Li, Yoriko Heianza, Kyle D Staller, Andrew T Chan, Eric B Rimm, Kathryn M Rexrode, Lu Qi, Wenjie Ma, Yanping Li, Yoriko Heianza, Kyle D Staller, Andrew T Chan, Eric B Rimm, Kathryn M Rexrode, Lu Qi

Abstract

Emerging evidence suggests a potential impact of gastrointestinal function on cardiometabolic risk. Abnormal bowel movements have been related to various cardiovascular risk factors such as dyslipidemia, hypertension, diabetes, and altered metabolism of bile acids and gut microbiota. However, little is known about whether bowel movement frequency affects risk of cardiovascular disease (CVD) and mortality. In the Nurses' Health Study, bowel movement frequency was self-reported in 1982 by 86,289 women free from CVD and cancer. During up to 30 years of follow-up, we documented 7,628 incident CVD cases and 21,084 deaths. After adjustment for dietary intake, lifestyle, medication use, and other risk factors, as compared with women with daily bowel movement, having bowel movements more than once daily was significantly associated with increased risk of CVD (hazard ratio [HR]: 1.13; 95% confidence interval [CI]: 1.05-1.21), total mortality (HR: 1.17; 95% CI: 1.12-1.22), and cardiovascular mortality (HR: 1.17; 95% CI: 1.07-1.28). With further adjustment for body mass index and diabetes status, the association with total mortality remained significant (HR: 1.10; 95% CI: 1.06-1.15), whereas the associations with incident CVD and cardiovascular mortality were no longer significant. Our results suggest increased bowel movement frequency is a potential risk factor for premature mortality.

Figures

Figure 1. Association between bowel movement frequency…
Figure 1. Association between bowel movement frequency and risk of total mortality according to baseline diabetes status.
Models were adjusted for the same covariates as shown in Model 4, Table 2.
Figure 2. Association between bowel movement frequency…
Figure 2. Association between bowel movement frequency and risk of total mortality according to baseline body mass index.
Models were adjusted for the same covariates as shown in Model 4, Table 2.

References

    1. Rogler G. & Rosano G. The heart and the gut. Eur Heart J 35, 426–430, 10.1093/eurheartj/eht271 (2014).
    1. Lv J. et al.. Gallstone Disease and the Risk of Ischemic Heart Disease. Arterioscler Thromb Vasc Biol 35, 2232–2237, 10.1161/ATVBAHA.115.306043 (2015).
    1. Olaiya M. T., Chiou H. Y., Jeng J. S., Lien L. M. & Hsieh F. I. Significantly increased risk of cardiovascular disease among patients with gallstone disease: a population-based cohort study. PLoS One 8, e76448, 10.1371/journal.pone.0076448 (2013).
    1. Ruhl C. E. & Everhart J. E. Gallstone disease is associated with increased mortality in the United States. Gastroenterology 140, 508–516, 10.1053/j.gastro.2010.10.060 (2011).
    1. Andersen N. N. & Jess T. Risk of cardiovascular disease in inflammatory bowel disease. World J Gastrointest Pathophysiol 5, 359–365, 10.4291/wjgp.v5.i3.359 (2014).
    1. Portincasa P., Moschetta A. & Palasciano G. Cholesterol gallstone disease. Lancet 368, 230–239, 10.1016/S0140-6736(06)69044-2 (2006).
    1. Agouridis A. P., Elisaf M. & Milionis H. J. An overview of lipid abnormalities in patients with inflammatory bowel disease. Ann Gastroenterol 24, 181–187 (2011).
    1. Wu T. et al.. Gut microbiota dysbiosis and bacterial community assembly associated with cholesterol gallstones in large-scale study. BMC Genomics 14, 669, 10.1186/1471-2164-14-669 (2013).
    1. Willing B. P. et al.. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 139, 1844-1854 e1841, 10.1053/j.gastro.2010.08.049 (2010).
    1. Ponnusamy K., Choi J. N., Kim J., Lee S. Y. & Lee C. H. Microbial community and metabolomic comparison of irritable bowel syndrome faeces. J Med Microbiol 60, 817–827, 10.1099/jmm.0.028126-0 (2011).
    1. Attaluri A., Jackson M., Valestin J. & Rao S. S. Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS. Am J Gastroenterol 105, 1407–1411, 10.1038/ajg.2009.655 (2010).
    1. Kim S. E. et al.. Change of Fecal Flora and Effectiveness of the Short-term VSL#3 Probiotic Treatment in Patients With Functional Constipation. J Neurogastroenterol Motil 21, 111–120, 10.5056/jnm14048 (2015).
    1. Tang W. H. & Hazen S. L. The contributory role of gut microbiota in cardiovascular disease. J Clin Invest 124, 4204–4211, 10.1172/JCI72331 (2014).
    1. Wang Z. et al.. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57–63, 10.1038/nature09922 (2011).
    1. Tang W. H. et al.. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 368, 1575–1584, 10.1056/NEJMoa1109400 (2013).
    1. Qin J. et al.. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55–60, 10.1038/nature11450 (2012).
    1. Talley N. J. Functional gastrointestinal disorders as a public health problem. Neurogastroenterol Motil 20 Suppl 1, 121–129, 10.1111/j.1365-2982.2008.01097.x (2008).
    1. Talley N. J., Jones M., Nuyts G. & Dubois D. Risk factors for chronic constipation based on a general practice sample. Am J Gastroenterol 98, 1107–1111, 10.1111/j.1572-0241.2003.07465.x (2003).
    1. Salmoirago-Blotcher E., Crawford S., Jackson E., Ockene J. & Ockene I. Constipation and risk of cardiovascular disease among postmenopausal women. Am J Med 124, 714–723, 10.1016/j.amjmed.2011.03.026 (2011).
    1. Guo Y. et al.. Irritable bowel syndrome is positively related to metabolic syndrome: a population-based cross-sectional study. PLoS One 9, e112289, 10.1371/journal.pone.0112289 (2014).
    1. Abrahamsson H., Ostlund-Lindqvist A. M., Nilsson R., Simren M. & Gillberg P. G. Altered bile acid metabolism in patients with constipation-predominant irritable bowel syndrome and functional constipation. Scand J Gastroenterol 43, 1483–1488, 10.1080/00365520802321212 (2008).
    1. Chang J. Y., Locke G. R., Schleck C. D., Zinsmeister A. R. & Talley N. J. Risk factors for chronic constipation and a possible role of analgesics. Neurogastroenterol Motil 19, 905–911, 10.1111/j.1365-2982.2007.00974.x (2007).
    1. Everhart J. E. et al.. A longitudinal survey of self-reported bowel habits in the United States. Dig Dis Sci 34, 1153–1162 (1989).
    1. Clouse R. E. & Lustman P. J. Gastrointestinal symptoms in diabetic patients: lack of association with neuropathy. Am J Gastroenterol 84, 868–872 (1989).
    1. Maleki D. et al.. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med 160, 2808–2816 (2000).
    1. Kubota Y., Iso H. & Tamakoshi A. Bowel Movement Frequency, Laxative Use, and Mortality From Coronary Heart Disease and Stroke Among Japanese Men and Women: The Japan Collaborative Cohort (JACC) Study. J Epidemiol, 10.2188/jea.JE20150123 (2015).
    1. Honkura K. et al.. Defecation frequency and cardiovascular disease mortality in Japan: The Ohsaki cohort study. Atherosclerosis 246, 251–256, 10.1016/j.atherosclerosis.2016.01.007 (2016).
    1. Sanjoaquin M. A., Appleby P. N., Spencer E. A. & Key T. J. Nutrition and lifestyle in relation to bowel movement frequency: a cross-sectional study of 20630 men and women in EPIC-Oxford. Public Health Nutr 7, 77–83 (2004).
    1. Collet T. H. et al.. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 172, 799–809, 10.1001/archinternmed.2012.402 (2012).
    1. Maggio M. et al.. Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med 173, 518–523, 10.1001/jamainternmed.2013.2851 (2013).
    1. DuPont A. W. & DuPont H. L. The intestinal microbiota and chronic disorders of the gut. Nat Rev Gastroenterol Hepatol 8, 523–531, 10.1038/nrgastro.2011.133 (2011).
    1. Talley N. J., Weaver A. L., Zinsmeister A. R. & Melton L. J. 3rd. Functional constipation and outlet delay: a population-based study. Gastroenterology 105, 781–790 (1993).
    1. Drossman D. A. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 130, 1377–1390, 10.1053/j.gastro.2006.03.008 (2006).
    1. Conlon M. A. & Bird A. R. The impact of diet and lifestyle on gut microbiota and human health. Nutrients 7, 17–44, 10.3390/nu7010017 (2015).
    1. Koeth R. A. et al.. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 19, 576–585, 10.1038/nm.3145 (2013).
    1. Ley R. E. et al.. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 102, 11070–11075, 10.1073/pnas.0504978102 (2005).
    1. Turnbaugh P. J. et al.. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027–1031, 10.1038/nature05414 (2006).
    1. Colditz G. A. et al.. Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol 123, 894–900 (1986).
    1. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. Diabetes 28, 1039–1057 (1979).
    1. Rimm E. B. et al.. Validity of self-reported waist and hip circumferences in men and women. Epidemiology 1, 466–473 (1990).
    1. Wolf A. M. et al.. Reproducibility and validity of a self-administered physical activity questionnaire. Int J Epidemiol 23, 991–999 (1994).
    1. Willett W. C. et al.. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol 122, 51–65 (1985).
    1. Li Y. et al.. Saturated Fats Compared With Unsaturated Fats and Sources of Carbohydrates in Relation to Risk of Coronary Heart Disease: A Prospective Cohort Study. J Am Coll Cardiol 66, 1538–1548, 10.1016/j.jacc.2015.07.055 (2015).
    1. Rose G. A., Blackburn H., Gillum R. F. & Prineas R. J. Cardiovascular Survey Methods, Geneva, Switzerland: World Health Organization. World Health Organization monograph series (1982).

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe